abnormal forebrain development, abnormal induced retina neovascularization, abnormal leukocyte adhesion, abnormal macrophage physiology, abnormal thrombosis, abnormal vascular smooth muscle physiology, abnormal vascular wound healing, abnormal ventricular thrombosis, abnormal vitelline vasculature morphology, absent vitelline blood vessels, cardiac fibrosis, decreased circulating interleukin-1 beta level, decreased circulating interleukin-6 level, decreased circulating tumor necrosis factor level, decreased embryo size, decreased interleukin-6 secretion, decreased partial thromboplastin time, decreased sensitivity to induced morbidity/mortality, decreased susceptibility to endotoxin shock, disorganized yolk sac vascular plexus, distended pericardium, embryo tissue necrosis, embryonic growth retardation, embryonic lethality during organogenesis, complete penetrance, embryonic lethality during organogenesis, incomplete penetrance, enlarged pericardium, hematopoietic system phenotype, homeostasis/metabolism phenotype, immune system phenotype, impaired leukocyte tethering or rolling, increased circulating factor IX level, increased circulating factor VIII level, increased circulating factor XI level, increased lung adenoma incidence, increased lung carcinoma incidence, neonatal lethality, incomplete penetrance, pale yolk sac, postnatal lethality, postnatal lethality, complete penetrance, pregnancy-related premature death, premature death, prenatal lethality, complete penetrance